Currently, two recently approved KIT inhibitors avapritinib (for PDGFRA-D842V) and ripretinib as 4th line therapy for GIST, hold promise to treat some of the secondary resistance mutations of KIT/PDGFRA in metastatic GIST [36]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.